Merck Subsidiary Thailand Merger Sub Launches $53 per Share Tender Offer for Terns Pharmaceuticals

Why It Matters

The deal represents Merck’s strategic expansion into Terns’ oncology pipeline and will force market participants to reassess positions in Terns securities, especially options and futures that may be adjusted or exposed to delivery risk.

Key Takeaways

• Merck subsidiary offers $53 cash per Terns share in tender.
• Offer expires 11:59 PM ET May 4, 2026, covering all outstanding shares.
• Tender could trigger OCC‑mandated options contract adjustments under Rule 2803.
• Uncovered option writers face delivery risk if merger closes after expiry.
• NSCC protect provisions may impose liability for late securities delivery.

Pulse Analysis

, proposing $53 per share. The price represents a premium to Terns’ recent trading range, underscoring Merck’s confidence in the biotech’s late‑stage oncology assets and its pipeline of targeted therapies. By acquiring Terns, Merck aims to bolster its position in the competitive cancer‑treatment market and accelerate the development of next‑generation immunotherapies. m.

ET on May 4, 2026, is open to all shareholders. The tender triggers a cascade of regulatory and clearing‑house actions, most notably the need for options and futures contracts on TERN to be adjusted under OCC Rule 2803(c)(3)(ii). Market makers and institutional investors must monitor the potential conversion of existing options into cash‑settled equivalents once the merger closes. Uncovered call writers and short futures holders face heightened delivery risk because settlement typically occurs one business day after exercise, which may miss the tender deadline. NSCC’s protect provisions can impose liability on parties that fail to deliver securities on time, adding another layer of complexity for traders.

Beyond the immediate pricing dynamics, the transaction signals a broader trend of large pharmaceutical firms consolidating niche biotech innovators to diversify their pipelines. For Terns shareholders, the $53 cash consideration offers a clear exit, while for Merck it secures a strategic foothold in emerging cancer modalities. Investors should evaluate the likelihood of the merger’s completion, the timing of any contract adjustments, and the impact on related derivative positions. Staying informed about OCC notices and NSCC guidelines will be essential to mitigate unexpected exposure as the deadline approaches.

Deal Summary

Thailand Merger Sub, Inc., a wholly‑owned subsidiary of Merck Sharp & Dohme LLC (Merck & Co.), has announced a tender offer to acquire all outstanding common shares of Terns Pharmaceuticals, Inc. at $53.00 cash per share. The offer expires at 11:59 PM ET on May 4, 2026. Upon completion, the transaction will result in a merger of Terns into Merck’s portfolio.